Pacific Biosciences Of California | PACB - Operating Profit


Pacific Biosciences Of California reported $-53.19M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agilent USD 399M 46M Mar/2026
Bruker USD 10.2M 66.1M Mar/2026
Danaher USD 1.34B 158M Mar/2026
General Electric Aerospace USD 2.32B 549M Mar/2026
Illumina USD 239M 17M Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Quidel USD -31.8M 5.5M Mar/2026
Revvity USD 82.77M 63.06M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Standard Biotools USD -21.92M 1.55M Dec/2025
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Waters USD 148M 122.52M Mar/2026